Erasca (ERAS) Valuation Check After S&P Biotechnology Select Industry Index Inclusion [Yahoo! Finance]
Erasca, Inc. (ERAS)
Company Research
Source: Yahoo! Finance
See our latest analysis for Erasca. The index news lands on top of an already strong run, with the share price up 18.69 percent over the last month and an 89.50 percent 3 month share price return signaling building momentum, even though the 3 year total shareholder return remains negative. If this kind of rerating story appeals to you, it could be worth scanning other discovery phase names across healthcare stocks for fresh ideas beyond Erasca. With shares still trading at roughly half of consensus target despite the recent surge, is Erasca an overlooked rerating story with more room to run, or are investors already baking in years of future pipeline success? Erasca trades at a price-to-book ratio of 2.8 times, which positions the stock almost in line with its closest peer group on this metric. The price-to-book multiple compares the company's market value to its net assets and is often used for early stage or unprofitable biotechs where earnings are not yet meaningful. For
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Platform Technologies Drive $211B Surge in Precision Cancer TreatmentPR Newswire
- Erasca (NASDAQ:ERAS) was given a new $5.00 price target on by analysts at Mizuho.MarketBeat
- Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results [Yahoo! Finance]Yahoo! Finance
- Erasca to Present at the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Erasca to Present at the 8th Annual Evercore Healthcare ConferenceGlobeNewswire
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 12/15/25 - Form 144
- 11/17/25 - Form 144
- 11/14/25 - Form SCHEDULE
- ERAS's page on the SEC website